We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Fusion Antibodies Plc | LSE:FAB | London | Ordinary Share | GB00BDQZGK16 | ORD 4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 3.40 | 3.30 | 3.50 | 3.40 | 3.40 | 3.40 | 189,748 | 08:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 2.9M | -2.6M | -0.0437 | -0.78 | 2.02M |
From Nov 2023 to May 2024
By Ian Walker
Fusion Antibodies shares rose 58% after the company said that it has signed a collaboration agreement with the U.S. National Cancer Institute toward the discovery of potential therapeutic antibodies.
Shares at 1242 GMT on Tuesday were up 2.0 pence at 5.45 pence, marking their best one-day percentage performance since September 2020.
Under the deal the U.K. biotechnology company will provide the NCI with access to its OptiMAL technology against an agreed number of cancer targets for up to two years. The parties will work together to ensure successful validation of the technology and jointly publish any results.
NCI, part of the U.S. National Institutes of Health, is the U.S. federal government's main agency for cancer research and training.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
November 28, 2023 08:08 ET (13:08 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Fusion Antibodies Chart |
1 Month Fusion Antibodies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
